Compare Stocks: TEVA, PFE, BMY, and SNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$67.30 +0.4%	$60.77	$42.52 ▼ $68.64	$136.88B	0.22	12.37 million shs	6.81 million shs
PFE Pfizer	$27.97 -0.4%	$25.34	$23.58 ▼ $28.75	$159.99B	0.34	41.07 million shs	23.81 million shs
SNY Sanofi	$45.69 -0.3%	$43.48	$40.89 ▼ $52.68	$111.16B	0.35	3.15 million shs	1.72 million shs
TEVA Teva Pharmaceutical Industries	$36.96 -1.0%	$33.88	$17.82 ▼ $37.83	$43.51B	0.86	6.10 million shs	3.34 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.36%	+4.00%	+8.46%	+15.65%	+40.67%
PFE Pfizer	-0.11%	+4.05%	+14.04%	+8.15%	+8.30%
SNY Sanofi	-0.35%	+2.88%	+5.40%	+3.49%	-11.02%
TEVA Teva Pharmaceutical Industries	-1.11%	+1.17%	+20.05%	+6.63%	+100.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$67.30 +0.4%	$60.77	$42.52 ▼ $68.64	$136.88B	0.22	12.37 million shs	6.81 million shs
PFE Pfizer	$27.97 -0.4%	$25.34	$23.58 ▼ $28.75	$159.99B	0.34	41.07 million shs	23.81 million shs
SNY Sanofi	$45.69 -0.3%	$43.48	$40.89 ▼ $52.68	$111.16B	0.35	3.15 million shs	1.72 million shs
TEVA Teva Pharmaceutical Industries	$36.96 -1.0%	$33.88	$17.82 ▼ $37.83	$43.51B	0.86	6.10 million shs	3.34 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.36%	+4.00%	+8.46%	+15.65%	+40.67%
PFE Pfizer	-0.11%	+4.05%	+14.04%	+8.15%	+8.30%
SNY Sanofi	-0.35%	+2.88%	+5.40%	+3.49%	-11.02%
TEVA Teva Pharmaceutical Industries	-1.11%	+1.17%	+20.05%	+6.63%	+100.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.56	Moderate Buy	$66.06	-1.85% Downside
PFE Pfizer	2.19	Hold	$28.28	1.11% Upside
SNY Sanofi	2.40	Hold	$49.50	8.34% Upside
TEVA Teva Pharmaceutical Industries	2.90	Moderate Buy	$42.22	14.25% Upside

Current Analyst Ratings Breakdown

Latest TEVA, PFE, BMY, and SNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/18/2026	BMY Bristol Myers Squibb	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/17/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/12/2026	TEVA Teva Pharmaceutical Industries	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $42.00
8/7/2026	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $31.00
8/5/2026	BMY Bristol Myers Squibb	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform ➝ Strong-Buy
8/5/2026	BMY Bristol Myers Squibb	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy
8/5/2026	BMY Bristol Myers Squibb	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/5/2026	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/5/2026	BMY Bristol Myers Squibb	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/5/2026	BMY Bristol Myers Squibb	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$49.19B	2.79	$8.17 per share	8.24	$9.09 per share	7.40
PFE Pfizer	$62.58B	2.55	$4.38 per share	6.38	$15.26 per share	1.83
SNY Sanofi	$49.35B	2.24	$7.04 per share	6.49	$33.27 per share	1.37
TEVA Teva Pharmaceutical Industries	$17.26B	2.50	$3.69 per share	10.01	$6.88 per share	5.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$4.54	14.82	10.45	0.17	18.87%	66.90%	14.74%	10/29/2026 (Estimated)
PFE Pfizer	$7.77B	$0.76	36.80	9.55	N/A	6.80%	19.63%	8.46%	11/3/2026 (Estimated)
SNY Sanofi	$8.84B	$1.91	23.92	8.74	1.13	8.66%	14.19%	7.95%	10/23/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	61.60	12.20	3.99	4.08%	32.64%	6.34%	11/4/2026 (Estimated)

Latest TEVA, PFE, BMY, and SNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	PFE Pfizer	$0.6820	$0.77	+$0.0880	-$0.04	$14.40 billion	$15.03 billion
7/30/2026	Q2 2026	BMY Bristol Myers Squibb	$1.60	$2.04	+$0.44	$1.62	$11.74 billion	$12.97 billion
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	3.74%	+1.61%	55.51%	17 Years
PFE Pfizer	$1.72	6.15%	-13.20%	226.32%	16 Years
SNY Sanofi	$1.76	3.85%	+6.46%	92.15%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest TEVA, PFE, BMY, and SNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/24/2026	PFE Pfizer	quarterly	$0.43	7.01%	7/24/2026	7/24/2026	9/1/2026
6/17/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.34%	7/2/2026	7/2/2026	8/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	1.89	1.53	1.38
PFE Pfizer	0.71	1.27	0.96
SNY Sanofi	0.21	0.99	0.64
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
PFE Pfizer	68.36%
SNY Sanofi	14.03%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
PFE Pfizer	0.62%
SNY Sanofi	1.00%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

TEVA, PFE, BMY, and SNY Headlines

Recent News About These Companies

Teva share price hits 10-year high

August 23 at 1:17 PM | en.globes.co.ilE

X Square Capital LLC Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

August 23 at 6:39 AM | marketbeat.com

TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

August 20, 2026 | finance.yahoo.com

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

August 20, 2026 | finance.yahoo.com

TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

August 20, 2026 | zacks.com

AUPH Stock Rallies 6% After-Hours — Here’s Why

August 19, 2026 | stocktwits.comS

Aurinia Settles Patent Litigation with Teva

August 19, 2026 | businesswire.com

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 12-Month High - What's Next?

August 19, 2026 | marketbeat.com

FDA accepts Teva's NDA for ecopipam, grants priority review for pediatric Tourette syndrome

August 19, 2026 | thepharmaletter.comT

Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?

August 19, 2026 | finance.yahoo.com

Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?

August 19, 2026 | zacks.com

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

August 19, 2026 | globenewswire.com

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

August 17, 2026 | finance.yahoo.com

Empowered Funds LLC Increases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

August 17, 2026 | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, Barclays Analyst Says

August 14, 2026 | americanbankingnews.com

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High After Analyst Upgrade

August 13, 2026 | marketbeat.com

Humana agrees not to reference Teva's Israel ties at US drug trial

August 13, 2026 | reuters.com

Teva Pharmaceutical Industries Ltd: Moody's Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

August 13, 2026 | finanznachrichten.de

ADAMA Appoints Orly Pascal as Chief Human Resources Officer

August 13, 2026 | finance.yahoo.com

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

August 12, 2026 | finance.yahoo.com

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

August 12, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, PFE, BMY, and SNY Company Descriptions

Bristol Myers Squibb NYSE:BMY

$67.30 +0.29 (+0.43%)

Closing price 08/24/2026 03:59 PM Eastern

Extended Trading

$67.47 +0.17 (+0.26%)

As of 04:03 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Pfizer NYSE:PFE

$27.97 -0.10 (-0.36%)

Closing price 08/24/2026 03:59 PM Eastern

Extended Trading

$28.04 +0.07 (+0.24%)

As of 04:27 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sanofi NASDAQ:SNY

$45.69 -0.16 (-0.35%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$45.68 -0.01 (-0.02%)

As of 04:29 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Teva Pharmaceutical Industries NYSE:TEVA

$36.96 -0.38 (-1.03%)

Closing price 08/24/2026 03:59 PM Eastern

Extended Trading

$36.94 -0.01 (-0.03%)

As of 04:03 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, PFE, BMY, and SNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, PFE, BMY, and SNY Earnings

Compare Dividends

Latest TEVA, PFE, BMY, and SNY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, PFE, BMY, and SNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, PFE, BMY, and SNY Company Descriptions

Bristol Myers Squibb NYSE:BMY

Pfizer NYSE:PFE

Sanofi NASDAQ:SNY

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, PFE, BMY, and SNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, PFE, BMY, and SNY Earnings

Compare Dividends

Latest TEVA, PFE, BMY, and SNY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, PFE, BMY, and SNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, PFE, BMY, and SNY Company Descriptions

Bristol Myers Squibb NYSE:BMY

Pfizer NYSE:PFE

Sanofi NASDAQ:SNY

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools